奥布替尼用于继发性进展型多发性硬化症患者的研究
一项比较奥拉布替尼与安慰剂治疗非活动性继发进展型多发性硬化症患者的3期随机双盲疗效和安全性研究
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with non-active Secondary Progress MS. Patients will be treated for approximately 24 to 60 months, with a minimum treatment duration of 12 months. The study will enroll approximately 990 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.
研究概览
详细说明
This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with naSPMS. The study will enroll approximately 990 subjects in a 2:1 randomization (orelabrutinib: placebo), globally.
The study consists of the following periods:
- Screening Period: Up to 4 weeks.
- Treatment Period: The duration of treatment will vary for individual participants ranging from approximately 24 to 60 months, depending on the time of recruitment. A month is defined as a period of 28 days by convention.
- Double-blinded (DB) Treatment: All eligible participants will be randomized at 2:1 ratio to accept orelabrutinib QD or placebo during the DB treatment period. The study will be unblinded when all participants in the DB period have reached a minimum treatment duration of 12 months at the time of primary analysis timing cutoff.
- Open-label (OL) Treatment: Participants with 24-week CDP as assessed by EDSS are eligible for 2-year open-label orelabrutinib treatment.
- Safety Follow-Up Period: It will last 4 weeks. The safety follow-up period will begin when the participants discontinue from the treatment before the end of the trial for any reasons or complete the trial but do not enter the long-term safety study (LTS) (see below).
All active study participants will have a final end of study (EOS) visit within 4 weeks of the study end date. Participants who are receiving IMP in DB or OL but do not consent to or are not eligible for enrollment in the LTS study, must return for a final safety follow-up visit 4 weeks later. For participants who intend and are eligible to join the LTS, open-label treatment with orelabrutinib will continue and no safety follow-up will occur.
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Patient and Medical Information
- 电话号码:833-269-4696
- 邮箱:clinicaltrialsinfo@zenasbio.com
研究联系人备份
- 姓名:Patient and Medical Information
- 电话号码:833-269-4696
- 邮箱:clinialtrialsinfo@zenasbio.com
学习地点
-
-
-
Vinnytsia、乌克兰、21009
- 招聘中
- Medical Clinical Investigational Center of Medical Center LLC Health Clinic
-
-
Chernivtsi Oblast
-
Chernivtsi、Chernivtsi Oblast、乌克兰、58023
- 招聘中
- Regional Municipal Non-commercial Enterprise Chernivtsi Emergency Medical Hospital
-
-
Ivano-Frankivs'k Oblast
-
Ivano-Frankivsk、Ivano-Frankivs'k Oblast、乌克兰、76018
- 招聘中
- CNE City Clinical Hospital #1 of Ivano-Frankivsk council
-
-
Lviv Oblast
-
Lviv、Lviv Oblast、乌克兰、79000
- 招聘中
- Limited Liability Company Medical Center Neuroclinic
-
Lviv、Lviv Oblast、乌克兰、79029
- 招聘中
- Limited Liability Company "Neurofocus"
-
-
-
-
-
Tbilisi、乔治亚州、0114
- 招聘中
- LTD Pineo Medical Ecosystem
-
Tbilisi、乔治亚州、0186
- 招聘中
- Raymann, LLC
-
Tbilisi、乔治亚州、0159
- 招聘中
- NNLE Jo Ann University Hospital
-
Tbilisi、乔治亚州、0186
- 招聘中
- Caucasus Medical Center Ltd
-
-
K'alak'i T'bilisi
-
Tbilisi、K'alak'i T'bilisi、乔治亚州、0114
- 招聘中
- JSC Curatio
-
-
Saburtalo
-
Tbilisi、Saburtalo、乔治亚州、0160
- 招聘中
- MD Georgia Staff Physician MediClub Georgia
-
-
-
-
-
Pleven、保加利亚、5800
- 招聘中
- Avis Medica Hospital Pleven
-
-
Plovdiv
-
Plovdiv、Plovdiv、保加利亚、4000
- 招聘中
- Medical Center Nevrocentrum
-
-
Sofia
-
Sofia、Sofia、保加利亚、1680
- 招聘中
- Diagnostic and Consultative Center Convex
-
Sofia、Sofia、保加利亚、1510
- 招聘中
- Medical Center Hera EOOD
-
-
Tarnovo
-
Veliko Tarnovo、Tarnovo、保加利亚、5000
- 招聘中
- Medical Center Medica Plus OOD
-
-
-
-
-
Zagreb、克罗地亚、10 000
- 招聘中
- Klinicki Bolnicki Centar Zagreb-Rebro
-
-
-
-
-
Budapest、匈牙利、1145
- 招聘中
- National Institute of Clinical Neurosciences
-
Tatabánya、匈牙利、2800
- 招聘中
- Komarom-Esztergom Varmegyei Szent Borbala Korhaz
-
-
Komarom-Esztergom Vamegye
-
Esztergom、Komarom-Esztergom Vamegye、匈牙利、2500
- 招聘中
- Valeomed Kft.
-
-
-
-
-
Kragujevac、塞尔维亚、34000
- 招聘中
- University Clinical Centre of Kragujevac
-
Niš、塞尔维亚、18000
- 招聘中
- Clinic of Neurology - Clinical Center Nis
-
-
Belgrade
-
Belgrade、Belgrade、塞尔维亚、11000
- 招聘中
- University Clinical Centre of Serbia
-
-
-
-
Athens
-
Cholargós、Athens、希腊、15562
- 招聘中
- Metropolitan General Hospital
-
-
Attica
-
Athens、Attica、希腊、11526
- 招聘中
- Errikos Dunant Hospital
-
-
-
-
Hesse
-
Bad Homburg、Hesse、德国、61348
- 招聘中
- Zentrum fur klinische Forschung Dr.Scholl GmbH
-
-
-
-
Chieti
-
Chieti、Chieti、意大利、66100
- 招聘中
- University G. D'Annunzio of Chieti-Pescara
-
-
Isernia/Molise
-
Pozzilli、Isernia/Molise、意大利、86077
- 招聘中
- IRCCS Istituto Neurologico Mediterraneo Neuromed
-
-
-
-
-
Choceň、捷克语、56501
- 招聘中
- NEUROHK, s.r.o.
-
Jihlava、捷克语、58601
- 招聘中
- Regional Hospital Jihlava
-
-
-
-
Limburg
-
Overpelt、Limburg、比利时、3900
- 招聘中
- MS-Netwerk Limburg - Revalidatie
-
-
-
-
Gard
-
Nîmes、Gard、法国、30029
- 招聘中
- Centre Hospitalier Universitaire de Nimes (CHU) - Hopital Universitaire Caremeau
-
-
-
-
-
Lublin、波兰、20-064
- 招聘中
- Galen Clinic
-
Poznan、波兰、15-540
- 招聘中
- Prywatna Lecznica Certus Sp. z o.o.
-
Szczecin、波兰、70-111
- 招聘中
- EUROMEDIS Osrodek Badan Klinicznych
-
Żory、波兰、44-240
- 招聘中
- Centrum Medyczne ProNeuro Żory
-
-
Kuyavian-Pomeranian Voivodeship
-
Bydgoszcz、Kuyavian-Pomeranian Voivodeship、波兰、85-605
- 招聘中
- Centrum Medyczne INTERCOR Sp. z o.o.
-
-
Lublin Voivodeship
-
Lublin、Lublin Voivodeship、波兰、20-601
- 招聘中
- Malva Trials
-
Lublin、Lublin Voivodeship、波兰、20-064
- 招聘中
- Instytut Naukowo-Badawczy w Lublinie Sp. z o.o.
-
Lublin、Lublin Voivodeship、波兰、20-064
- 招聘中
- NZOZ Neuromed M. i M. Nastaj Sp.P
-
-
Lubusz Voivodeship
-
Nowa Sól、Lubusz Voivodeship、波兰、67-100
- 招聘中
- Twoja Przychodnia Centrum Medyczne Nowa Sól
-
-
Mazovian
-
Warsaw、Mazovian、波兰、02-172
- 招聘中
- MTZ Clinical Researcz Powered by pratia
-
-
Rzeszów
-
Rzeszów、Rzeszów、波兰、35-323
- 招聘中
- Nmedis sp. z o.o.
-
-
Silesian Voivodeship
-
Katowice、Silesian Voivodeship、波兰、40-081
- 招聘中
- Centrum Medyczne Pratia Katowice
-
Katowice、Silesian Voivodeship、波兰、40-571
- 招聘中
- MA-LEK Clinical Sp. z o.o.
-
Katowice、Silesian Voivodeship、波兰、40-584
- 招聘中
- NZOZ Novo Med
-
-
Upper Silesia
-
Katowice、Upper Silesia、波兰、40-686
- 招聘中
- Neuro Medic Clinic
-
-
Wielkopolska
-
Poznan、Wielkopolska、波兰、61-853
- 招聘中
- Nzoz Neuro-Kard Ilkowski I Partnerzy Spolka Partnerska Lekarzy
-
Poznan、Wielkopolska、波兰、60-324
- 招聘中
- Twoja Przychodnia PCM
-
-
Łódź Voivodeship
-
Lodz、Łódź Voivodeship、波兰、91-743
- 招聘中
- PRO SALUS Sp. z o.o. sp.k.
-
Lodz、Łódź Voivodeship、波兰、90-324
- 招聘中
- Centrum Neurologii Krzysztof Selmaj
-
-
-
-
-
Guaynabo、波多黎各、00969
- 招聘中
- Caribbean Center for Clinical Research
-
-
-
-
New South Wales
-
Kogarah、New South Wales、澳大利亚、2217
- 招聘中
- Southern Neurology Suite 2
-
-
-
-
Harju
-
Tallinn、Harju、爱沙尼亚、10617
- 招聘中
- Astra clinic (Clinic4U)
-
-
-
-
Kauno
-
Kaunas、Kauno、立陶宛、50161
- 招聘中
- Hospital of Lithuanian University of Health Sciences
-
-
-
-
Constanța County
-
Constanța、Constanța County、罗马尼亚、900123
- 招聘中
- Spital Clinic CF Constanta
-
-
Suceava
-
Radauti、Suceava、罗马尼亚、725400
- 招聘中
- Spitalul Municipal Sf. Doctori Cosma si Damian Radauti
-
-
-
-
Arizona
-
Phoenix、Arizona、美国、85032
- 招聘中
- Arizona Neuroscience Research, LLC
-
Scottsdale、Arizona、美国、85253
- 招聘中
- Perseverance Research Center, LLC (PRC)
-
-
California
-
Fullerton、California、美国、92835
- 招聘中
- Fullerton Neurology and Headache Center
-
Torrance、California、美国、90502-2006
- 招聘中
- Harbor-UCLA Medical Center - The Lundquist Institute (Los Angeles Biomedical Research Institute (LA BioMed))
-
West Hollywood、California、美国、90048
- 招聘中
- Regina Berkovich MD, PhD Inc
-
-
Florida
-
Boca Raton、Florida、美国、33487
- 招聘中
- SFM Clinical Research, LLC
-
Bradenton、Florida、美国、34209
- 招聘中
- Nova Clinical Research, LLC
-
Clearwater、Florida、美国、33761
- 招聘中
- MS and Neuromuscular Center of Excellence
-
Maitland、Florida、美国、32751
- 招聘中
- Neurology Associates
-
Naples、Florida、美国、34105
- 招聘中
- Aqualane Clinical Research
-
Tampa、Florida、美国、33612
- 招聘中
- University of South Florida Department of Neurology - MS Division
-
-
Indiana
-
Indianapolis、Indiana、美国、46256
- 招聘中
- Josephson Wallack Munshower Neurology, Pc Suite 225
-
-
Kansas
-
Kansas City、Kansas、美国、66160
- 招聘中
- University of Kansas Medical Center
-
Roeland Park、Kansas、美国、66205
- 招聘中
- KC Research Center, PA Neurology Research Dept
-
-
Massachusetts
-
Boston、Massachusetts、美国、02131
- 撤销
- Boston Clinical Trials
-
Worcester、Massachusetts、美国、01655
- 招聘中
- University of Massachusetts Memorial Medical Center
-
-
Michigan
-
Rochester Hills、Michigan、美国、48307
- 招聘中
- Profound Research LLC at Oakland Neurology Center
-
-
Missouri
-
St Louis、Missouri、美国、63110
- 招聘中
- Washington University School of Medicine
-
-
New Mexico
-
Albuquerque、New Mexico、美国、87131
- 招聘中
- University Of New Mexico School Of Medicine
-
-
New York
-
New York、New York、美国、10029
- 招聘中
- Mount Sinai Medical Center
-
-
Ohio
-
Columbus、Ohio、美国、43235
- 招聘中
- The Boster Center for Multiple Sclerosis
-
Columbus、Ohio、美国、43221
- 招聘中
- The Ohio State University Wexner Medical Center (OSUWMC)
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73104
- 招聘中
- OMRF Multiple Sclerosis Center of Excellence
-
-
South Carolina
-
Greenville、South Carolina、美国、29605
- 招聘中
- Premier Neurology
-
-
Tennessee
-
Cordova、Tennessee、美国、38018
- 招聘中
- Neurology Clinic, P.C.
-
-
Texas
-
San Antonio、Texas、美国、78258
- 招聘中
- Lone Star Neurology
-
Sherman、Texas、美国、75092
- 招聘中
- Texas Institute for Neurological Disorders - Sherman
-
-
-
-
A Coruña
-
A Coruña、A Coruña、西班牙、15006
- 招聘中
- Complejo Hospitalario Universitario A Coruña
-
-
Galicia
-
Vigo、Galicia、西班牙、36312
- 招聘中
- Hospital Alvaro Cunqueiro
-
-
Madrid
-
Madrid、Madrid、西班牙、28007
- 招聘中
- Hospital Gregorio Marañon
-
Majadahonda、Madrid、西班牙、28222
- 招聘中
- Hospital Universitario Puerta de Hierro de Majadahonda
-
-
Málaga
-
Málaga、Málaga、西班牙、29016
- 招聘中
- Vithas Hospital Parque San Antonio
-
-
Seville
-
Castilleja de la Cuesta、Seville、西班牙、41950
- 招聘中
- Hospital Vithas Nisa Sevilla
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- 18 to 60 years of age, inclusive, at the time of signing the informed consent.
- Participant must have a previous diagnosis of RRMS in accordance with 2024 McDonald criteria
- Participant must have a current diagnosis of SPMS in accordance with the clinical course criteria revised in 2013
- Participant must have documented evidence of disability progression independent of clinical relapse observed during the 24 months before screening. A written summary of the clinical evidence of disability progression must be discussed and aligned between the Investigator and the Sponsor's dedicated qualified person(s).
- Absence of clinical relapses for at least 24 months.
Exclusion Criteria:
- The patient has been diagnosed with primary progressive MS (PPMS) according to 2024 McDonald diagnostic criteria
- Immunologic disorder other than MS or any other conditions requiring corticosteroid therapy.
- History or current diagnosis of other neurological disorders that may mimic MS
- History or current diagnosis of progressive multifocal leukoencephalopathy
- Active, clinically significant viral, bacterial, or fungal infection
- History of any other significant active medical condition
- History of suicidal behavior within 6 months prior to Screening
- Any prior history of malignancy
- Patients on anticoagulation, or antiplatelet therapy
- Patients took strong/moderate CYP3A inhibitors or strong/moderate CYP3A inducers within 14 days
- Clinically significant laboratory abnormalities at Screening.
- Vaccination with live or live-attenuated virus vaccine within 1 month prior to Screening
- History of alcohol abuse or alcohol use disorder or other drug abuse within 12 months prior to screening.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Orelabrutinib Group
Orelabrutinib PO daily |
Orelabrutinib orally |
|
安慰剂比较:Placebo Group
Placebo PO daily |
Placebo orally |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Time to onset of confirmed disability progression (CDP) events, confirmed over at least 24 weeks
大体时间:Up to approximately 120 weeks
|
Expanded disability status scale (EDSS) score increase ≥ 1.0 point from baseline when the baseline score is ≤ 5.0, or ≥ 0.5 points from baseline when the baseline score is > 5.0 |
Up to approximately 120 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
12 Week CDP
大体时间:Up to approximately 120 weeks
|
Time to onset of CDP events on EDSS, confirmed over at least 12 weeks |
Up to approximately 120 weeks
|
|
T2 lesions on MRI
大体时间:Up to approximately 120 weeks
|
The total number of new or enlarging T2 lesions on MRI scans of the brain |
Up to approximately 120 weeks
|
|
24-week CDP-9-hole Peg Test
大体时间:Up to approximately 120 weeks
|
Time to onset of CDP events on 9-hole Peg Test (9HPT), defined as ≥ 20% increase on 9HPT from baseline, confirmed over at least 24 weeks |
Up to approximately 120 weeks
|
|
24-week CDP-T25FWT
大体时间:Up to approximately 120 weeks
|
Time to onset of CDP events on Timed 25-Foot Walk Test (T25FWT), defined as ≥ 20% increase on T25FWT from baseline, confirmed over at least 24 weeks |
Up to approximately 120 weeks
|
|
24-week CDI
大体时间:Up to approximately 120 weeks
|
Time to onset of confirmed disability improvement (CDI) events on EDSS, defined as ≥ 1.0-point decrease on the EDSS score from baseline when the baseline score is ≤ 5.0, or ≥ 0.5 points from baseline when the baseline score is > 5.0, confirmed over at least 24 weeks |
Up to approximately 120 weeks
|
|
24-week CDI-9HPT
大体时间:Up to approximately 120 weeks
|
Time to onset of CDI events on 9HPT, defined as ≥ 20% decrease on the 9HPT score from baseline, confirmed over at least 24 weeks |
Up to approximately 120 weeks
|
|
24-week CDI-T25FWT
大体时间:Up to approximately 120 weeks
|
Time to onset of CDI events on T25FWT, defined as ≥ 20% decrease on the T25FWT score from baseline, confirmed over at least 24 weeks |
Up to approximately 120 weeks
|
|
Symbol Digit Modalities Test
大体时间:Up to approximately 120 weeks
|
The change in cognitive function as assessed by Symbol Digit Modalities Test (SDMT) from baseline to each scheduled visit |
Up to approximately 120 weeks
|
|
Annualized relapse rate
大体时间:Up to approximately 120 weeks
|
Annualized relapse rate (ARR) during the study period assessed by protocol-defined adjudicated relapses |
Up to approximately 120 weeks
|
|
To evaluate the safety and tolerability of orelabrutinib
大体时间:Up to approximately 120 weeks
|
Safety as assessed by the nature, severity, and incidence of adverse events (AEs) (graded according to National Cancer Institute-Common Terminology Criteria for AEs, NCI-CTCAE version 5.0); |
Up to approximately 120 weeks
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- ZB020-03-002
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.